All In Biotech

Drug Trial Radar · NCT04041310

Nous-209 Genetic Vaccine for the Treatment of Microsatellite Unstable Solid Tumors

A Phase I/II, Multicenter, Open-Label Study of Nous-209 Genetic Vaccine for the Treatment of Microsatellite Unstable Solid Tumors

Last checked: Nov 20, 2026Latest source record: Feb 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingRandomized with 115 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

115

Planned (sponsor's estimate)

Start

Oct 21, 2019

Primary completion

Oct 30, 2026

Study completion Oct 30, 2026

Sponsor

Lead sponsor
Nouscom SRLIndustry
Sponsor type
Industry
Collaborators
Merck Sharp & Dohme LLC
First posted
Aug 1, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Ref: Protocol Version 9.1 05 December 2024. NOUS-209-01 is a multicenter, open-label, multiple cohorts, clinical study, designed to evaluate safety, tolerability, and immunogenicity, and to detect any preliminary evidence of anti-tumor activity of Nous-209 genetic polyvalent vaccine plus pembrolizumab combination therapy in adult subjects with unresectable or metastatic deficient mismatch repair (dMMR) or MSI-H CRC, gastric, or gastro-esophageal junction (G-E junction) tumors. Nous-209 is based on a heterologous prime/boost regimen composed of the Great Ape Adenovirus GAd20-209-FSP used for priming and Modified Vaccinia virus Ankara MVA-209-FSP used for boosting. The Phase I portion of the study is a first-in-human (FIH) clinical study with a primary objective to elucidate the safety and tolerability of Nous-209 in addition to establishing the recommended Phase 2 dose (RP2D), whereas the Phase II was introduced to assess efficacy as the primary objective.

Conditions

  • Solid Tumor, Adult

Interventions

  • GAd-209-FSP low doseBiological

    GAd20-209-FSP IP, low dose

  • MVA-209-FSP low doseBiological

    MVA-209-FSP IP, low dose

  • GAd-209-FSP high doseBiological

    GAd20-209-FSP IP, high dose

  • MVA-209-FSP high doseBiological

    MVA-209-FSP IP, high dose

  • GAd20-209-FSP, RP2DBiological

    GAd20-209-FSP IP, RP2D

  • MVA-209-FSP, RP2DBiological

    MVA-209-FSP IP, RP2D

  • KEYTRUDA®Drug

    anti-PD-1 checkpoint inhibitor (200 mg; Q3W)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Toxicity (DLT assessment), in Phase I, Cohort ATime frame: Within 28 days
  2. Safety and Tolerability, in Phase I, Cohort A and B.Time frame: Up to 110 weeks
  3. Overall Response Rate (ORR) at any time during the study, in Phase II (Cohort C and D).Time frame: 18 months

Locations

46 sites in 6 countries. Site status is shown where the registry gives one.

  • City of Hope Comprehensive Cancer Center

    Duarte, California

  • City of Hope Comprehensive Cancer Center

    Irvine, California

  • USC Norris Comprehensive Cancer Center

    Los Angeles, California

  • USC Norris Comprehensive Cancer Center

    Newport Beach, California

  • Mt. Sinai

    Miami Beach, Florida

  • Boca Raton Clinical Research

    Plantation, Florida

  • Goshen Center for Cancer Care

    Goshen, Indiana

  • Johns Hopkins University

    Baltimore, Maryland

  • Washington University School of Medicine, Division of Oncology

    St Louis, Missouri

  • Roswell Park Comprehensive Cancer Center

    Buffalo, New York

  • NYU Langone Medical Center

    New York, New York

  • Weill Cornell Medicine / New York-Presbyterian Hospital

    New York, New York

  • MD Anderson Cancer Center (MDACC)

    Houston, Texas

  • Cliniques Universitaires Saint-Luc - Centre du Cancer

    Brussels, Belgium

  • Centre Hospitalier de l'Ardenne - Libramont - Clinique du Sein

    Libramont, Belgium

  • CHU de Liège

    Liège, Belgium

  • Mount Sinai Hospital

    Toronto, Canada

  • Princess Margaret Cancer Center

    Toronto, Canada

  • Aorn Sg Moscati

    Avellino, Italy

  • Candiolo cancer Center,FPO IRCCS

    Candiolo, Italy

  • IRCCS Ospedale San Raffaele

    Milan, Italy

  • Fondazione IRCCS Istituto Nazionale dei Tumori

    Milan, Italy

  • Ospedale Niguarda

    Milan, Italy

  • AOUS Policlinico Le Scotte

    Siena, Italy

  • Hospital Universitario de A Coruna

    A Coruña, Spain

  • Hospital Del Mar

    Barcelona, Spain

  • Hospital Universitari Dexeus

    Barcelona, Spain

  • Hospital Vall d'Hebron

    Barcelona, Spain

  • Institut Catala d'Oncologia Hospitalet

    Barcelona, Spain

  • Hospital Clinic de Barcelona

    Barcelona, Spain

  • Hospital Universitario Reina Sofia

    Córdoba, Spain

  • Hospital Universitario Virgen de las Nieves

    Granada, Spain

  • Hospital General Universitario Gregorio Marañón

    Madrid, Spain

  • Clinica Universidad de Navarra

    Madrid, Spain

  • Hospital Universitario Fundación Jiménez Díaz

    Madrid, Spain

  • Hospital Universitario 12 de Octubre

    Madrid, Spain

  • Hospital Universitario La Paz

    Madrid, Spain

  • Hospital Universitario HM Sanchinarro

    Madrid, Spain

  • Clinica Universidad de Navarra

    Pamplona, Spain

  • Complejo Asistencial de Salamanca

    Salamanca, Spain

Showing 40 of 46 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.